ECSP056100A - Composiciones que contienen piperacilina y tazobactam útiles para injecciones - Google Patents
Composiciones que contienen piperacilina y tazobactam útiles para injeccionesInfo
- Publication number
- ECSP056100A ECSP056100A EC2005006100A ECSP056100A ECSP056100A EC SP056100 A ECSP056100 A EC SP056100A EC 2005006100 A EC2005006100 A EC 2005006100A EC SP056100 A ECSP056100 A EC SP056100A EC SP056100 A ECSP056100 A EC SP056100A
- Authority
- EC
- Ecuador
- Prior art keywords
- piperacilin
- injections
- compositions containing
- tazobactam
- useful
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000007924 injection Substances 0.000 title 1
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 title 1
- 229960003865 tazobactam Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229940126575 aminoglycoside Drugs 0.000 abstract 1
- 239000008135 aqueous vehicle Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008176 lyophilized powder Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 229940104641 piperacillin / tazobactam Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se ha comprobado que un agente quelante de ácido aminocaboxílico, de preferencia EDTA o una sal con el mismo compuesto, resultan útiles para inhibir la formación de partículas en combinaciones parenterales de piperacilina/tazobactam. Asimismo, la composición puede contener un buffer, de preferencia un citrato y un aminoglicósido, de manera opcional. El producto puede presentarse en forma de compuesto congelado que puede descongelarse para su uso. Asimismo, el producto puede presentarse en la forma de polvo liofilizado que puede reconstituirse agregando un vehículo acuoso para volver a formar la solución.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46280803P | 2003-04-14 | 2003-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP056100A true ECSP056100A (es) | 2006-03-01 |
Family
ID=32326726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005006100A ECSP056100A (es) | 2003-04-14 | 2005-10-14 | Composiciones que contienen piperacilina y tazobactam útiles para injecciones |
Country Status (35)
Country | Link |
---|---|
US (3) | US7498312B2 (es) |
EP (1) | EP1468697B1 (es) |
JP (1) | JP4644659B2 (es) |
KR (1) | KR100824554B1 (es) |
CN (1) | CN1802179B (es) |
AR (1) | AR043863A1 (es) |
AT (1) | ATE381947T1 (es) |
AU (1) | AU2004229407B2 (es) |
BR (1) | BRPI0409450B8 (es) |
CA (1) | CA2464258C (es) |
CH (1) | CH695185A9 (es) |
CL (1) | CL2004000782A1 (es) |
CO (1) | CO5700796A2 (es) |
CR (2) | CR8035A (es) |
CY (1) | CY1108064T1 (es) |
DE (1) | DE602004010862T2 (es) |
DK (1) | DK1468697T3 (es) |
EC (1) | ECSP056100A (es) |
ES (1) | ES2298672T3 (es) |
FR (1) | FR2853547B1 (es) |
GB (1) | GB2400557B (es) |
HK (1) | HK1069775A1 (es) |
IL (1) | IL171337A (es) |
MX (1) | MXPA05010996A (es) |
MY (1) | MY139099A (es) |
NO (1) | NO20054789L (es) |
NZ (1) | NZ543005A (es) |
PL (1) | PL1468697T3 (es) |
PT (1) | PT1468697E (es) |
RU (2) | RU2322980C2 (es) |
SA (1) | SA04250119B1 (es) |
SI (1) | SI1468697T1 (es) |
TW (1) | TWI308069B (es) |
WO (1) | WO2004091666A1 (es) |
ZA (1) | ZA200508315B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2526996T3 (da) | 2002-12-20 | 2019-12-02 | Xeris Pharmaceuticals Inc | Formulering til intrakutan injektion |
PL1468697T3 (pl) * | 2003-04-14 | 2008-05-30 | Wyeth Corp | Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań |
RU2007111484A (ru) * | 2004-10-14 | 2008-11-20 | Вайет (Us) | Составы, содержащие пиперациллин, тазобактам и аминокарбоновую кислоту в растворителе лактата натрия |
ATE476981T1 (de) * | 2004-12-02 | 2010-08-15 | Venus Remedies Ltd | Zusammensetzungen zur bekämpfung von beta- lactamase-vermittelter antibiotischer resistenz mittels beta-lactamase-hemmern für injektionen |
ES2284318B1 (es) * | 2005-04-13 | 2008-11-01 | Labiana Development, S.L. | Procedimiento de obtencion de una mezcla en polvo de una sal sodica de piperaciclina y tazobactama, util para su administracion por via inyectable. |
ITMI20051630A1 (it) * | 2005-09-02 | 2007-03-03 | Acs Dobfar Spa | Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi |
CN1927201B (zh) * | 2006-08-25 | 2011-06-01 | 天津和美生物技术有限公司 | 含哌拉西林的抗生素复方 |
CN102441169A (zh) * | 2006-08-25 | 2012-05-09 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和离子螯合剂的抗生素复方 |
CN101129383B (zh) * | 2006-08-25 | 2014-04-02 | 天津和美生物技术有限公司 | 含氨基糖苷类抗生素的抗生素复方 |
CN102210679B (zh) * | 2006-08-25 | 2013-03-13 | 天津和美生物技术有限公司 | 含哌拉西林的抗生素复方 |
CN101129381B (zh) * | 2006-08-25 | 2012-02-01 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和离子螯合剂的抗生素复方 |
CN101129382B (zh) | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和缓冲组分的抗生素复方 |
CN101265263B (zh) * | 2008-05-12 | 2010-06-02 | 海南百那医药发展有限公司 | 哌拉西林钠他唑巴坦钠复方注射剂的生产方法 |
JP5639471B2 (ja) * | 2008-07-28 | 2014-12-10 | 惠三 山口 | 感染症治療効果増強剤 |
JP5852316B2 (ja) * | 2010-03-30 | 2016-02-03 | 富山化学工業株式会社 | ピペラシリン含有懸濁液の製造法 |
US20120046225A1 (en) | 2010-07-19 | 2012-02-23 | The Regents Of The University Of Colorado, A Body Corporate | Stable glucagon formulations for the treatment of hypoglycemia |
NZ610247A (en) | 2010-11-25 | 2014-09-26 | Allecra Therapeutics Gmbh | Β-lactamase inhibitors and their use |
CN105853348B (zh) | 2011-03-10 | 2019-08-30 | Xeris药物公司 | 肠胃外注射用稳定溶液 |
WO2013067022A1 (en) | 2011-10-31 | 2013-05-10 | Xeris Pharmaceuticals, Inc. | Formulations for the treatment of diabetes |
TWI757799B (zh) | 2012-03-26 | 2022-03-11 | 日商參天製藥股份有限公司 | 水性點眼液之製造方法 |
US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
US8476425B1 (en) * | 2012-09-27 | 2013-07-02 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine compositions |
KR101816798B1 (ko) * | 2012-10-19 | 2018-01-10 | 주식회사유한양행 | 피페라실린 또는 그의 염, 타조박탐 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물 |
US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
KR102329764B1 (ko) | 2013-03-15 | 2021-11-23 | 머크 샤프 앤드 돔 코포레이션 | 세프톨로잔 항균성 조성물 |
US20140274991A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Ceftolozane pharmaceutical compositions |
WO2015035376A2 (en) | 2013-09-09 | 2015-03-12 | Calixa Therapeutics, Inc. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
US8906898B1 (en) | 2013-09-27 | 2014-12-09 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
KR102428675B1 (ko) | 2014-08-06 | 2022-08-02 | 엑스에리스 파머수티클스, 인크. | 페이스트의 피내 및/또는 피하 주사를 위한 주사기, 키트, 및 방법 |
JPWO2016056527A1 (ja) * | 2014-10-08 | 2017-07-20 | 沢井製薬株式会社 | 凍結乾燥製剤の製造方法 |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
RU2017144216A (ru) * | 2016-03-31 | 2019-06-18 | Вокхардт Лимитед | Антибактериальные композиции |
WO2018025248A1 (en) * | 2016-08-05 | 2018-02-08 | Jodas Expoim Private Limited | Edta injection and process for making the same |
EP4378463A2 (en) | 2017-06-02 | 2024-06-05 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
US11110054B2 (en) * | 2018-05-09 | 2021-09-07 | Slayback Pharma Llc | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
CN112618486B (zh) * | 2020-12-24 | 2023-07-18 | 浙江昂利康制药股份有限公司 | 一种注射用混悬油剂及其制备方法 |
CN113209030B (zh) * | 2021-04-27 | 2023-04-25 | 海南通用康力制药有限公司 | 哌拉西林钠他唑巴坦钠无菌粉针剂的制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4477452A (en) | 1981-03-26 | 1984-10-16 | American Cyanamid Company | Composition of matter comprising a lyophilized preparation of a penicillin derivative |
US4534977A (en) | 1981-03-26 | 1985-08-13 | American Cyanamid Company | Composition of matter comprising a low bulk density lyophilized preparation of Sodium Piperacillin |
US4562073A (en) | 1982-12-24 | 1985-12-31 | Taiho Pharmaceutical Company Limited | Penicillin derivatives |
US5763480A (en) * | 1994-02-14 | 1998-06-09 | The Jewish Hospital Of St. Louis | Inhibitors of cell-medicated disorders |
US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
US6207661B1 (en) * | 1999-02-22 | 2001-03-27 | Baxter International Inc. | Premixed formulation of piperacillin sodium and tazobactam sodium injection |
EP1499341A4 (en) * | 2002-04-18 | 2010-10-27 | Univ Iowa Res Found | PROCESS FOR INHIBITING AND PROCESSING BIOLOGICAL FILMS USING METAL CHELATORS |
PL1468697T3 (pl) * | 2003-04-14 | 2008-05-30 | Wyeth Corp | Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań |
WO2004098643A1 (en) * | 2003-04-14 | 2004-11-18 | Wyeth Holdings Corporation | Compositions containing piperacillin and tazobactam useful for injection |
US6900184B2 (en) | 2003-04-14 | 2005-05-31 | Wyeth Holdings Corporation | Compositions containing pipercillin and tazobactam useful for injection |
-
2004
- 2004-04-06 PL PL04076075T patent/PL1468697T3/pl unknown
- 2004-04-06 EP EP04076075A patent/EP1468697B1/en not_active Expired - Lifetime
- 2004-04-06 AT AT04076075T patent/ATE381947T1/de active
- 2004-04-06 ES ES04076075T patent/ES2298672T3/es not_active Expired - Lifetime
- 2004-04-06 SI SI200430609T patent/SI1468697T1/sl unknown
- 2004-04-06 CN CN2004800159296A patent/CN1802179B/zh not_active Expired - Lifetime
- 2004-04-06 DE DE602004010862T patent/DE602004010862T2/de not_active Expired - Lifetime
- 2004-04-06 DK DK04076075T patent/DK1468697T3/da active
- 2004-04-06 RU RU2005135135/15A patent/RU2322980C2/ru active
- 2004-04-06 PT PT04076075T patent/PT1468697E/pt unknown
- 2004-04-07 TW TW093109588A patent/TWI308069B/zh not_active IP Right Cessation
- 2004-04-07 NZ NZ543005A patent/NZ543005A/en unknown
- 2004-04-07 BR BRPI0409450A patent/BRPI0409450B8/pt active IP Right Grant
- 2004-04-07 KR KR1020057019689A patent/KR100824554B1/ko active IP Right Grant
- 2004-04-07 GB GB0407853A patent/GB2400557B/en not_active Expired - Fee Related
- 2004-04-07 WO PCT/US2004/010698 patent/WO2004091666A1/en active Application Filing
- 2004-04-07 MX MXPA05010996A patent/MXPA05010996A/es active IP Right Grant
- 2004-04-07 US US10/553,139 patent/US7498312B2/en active Active
- 2004-04-07 JP JP2006509780A patent/JP4644659B2/ja not_active Expired - Lifetime
- 2004-04-07 AU AU2004229407A patent/AU2004229407B2/en not_active Expired
- 2004-04-08 CA CA002464258A patent/CA2464258C/en not_active Expired - Lifetime
- 2004-04-09 MY MYPI20041292A patent/MY139099A/en unknown
- 2004-04-09 FR FR0403786A patent/FR2853547B1/fr not_active Expired - Fee Related
- 2004-04-12 CL CL200400782A patent/CL2004000782A1/es unknown
- 2004-04-13 AR ARP040101237A patent/AR043863A1/es active IP Right Grant
- 2004-04-13 CH CH00641/04A patent/CH695185A9/fr not_active IP Right Cessation
- 2004-05-18 SA SA4250119A patent/SA04250119B1/ar unknown
-
2005
- 2005-03-16 HK HK05102311A patent/HK1069775A1/xx not_active IP Right Cessation
- 2005-10-07 CR CR8035A patent/CR8035A/es unknown
- 2005-10-10 IL IL171337A patent/IL171337A/en active IP Right Grant
- 2005-10-13 ZA ZA200508315A patent/ZA200508315B/en unknown
- 2005-10-14 EC EC2005006100A patent/ECSP056100A/es unknown
- 2005-10-18 NO NO20054789A patent/NO20054789L/no not_active Application Discontinuation
- 2005-11-09 CO CO05114116A patent/CO5700796A2/es not_active Application Discontinuation
-
2007
- 2007-11-16 RU RU2007142454/15A patent/RU2007142454A/ru not_active Application Discontinuation
-
2008
- 2008-03-04 CR CR9792A patent/CR9792A/es not_active Application Discontinuation
- 2008-03-06 CY CY20081100258T patent/CY1108064T1/el unknown
-
2009
- 2009-02-13 US US12/370,794 patent/US7915229B2/en active Active
-
2011
- 2011-02-24 US US13/033,861 patent/US8133883B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP056100A (es) | Composiciones que contienen piperacilina y tazobactam útiles para injecciones | |
AR065887A1 (es) | Producto para el cuidado oral y metodos de uso y fabricacion de los mismos | |
AR084185A1 (es) | Composiciones dentifricas que contienen silicato de calcio y un aminoacido basico, metodo para el cuidado oral | |
PA8774901A1 (es) | Productos de cuidado oral y metodos para usar y fabricar el mismo | |
EA201000872A1 (ru) | Обогащенный бульонный кубик | |
ECSP088380A (es) | Composiciones ácidas para limpieza | |
GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
CO6290629A2 (es) | Composiciones de limpieza de amino ácido básico y métodos | |
NZ756322A (en) | Mechanism of urea/solid acid interaction under storage conditions and storage stable solid compositions comprising urea and acid | |
PE20120359A1 (es) | Formulacion con anticuerpo | |
MY160703A (en) | Crystalline forms of (r) -5- [3-chloro-4-(2,3-dihydroxy) - benz [z] ylidene] -2- ([z]-propylimino) -3-0-tolyl-thiazolidin-4-one | |
AR083775A1 (es) | Composicion dentifrica con astringencia reducida | |
PA8684501A1 (es) | Formulaciones de estrogenos conjugados y bazedoxifeno | |
AR060063A1 (es) | Material cementicio, formulacion de material cementicio y articulo obtenido | |
AR096705A1 (es) | Composición que comprende ácido glutámico-n,n-diacetato (glda), agua y enzima | |
BRPI0508798A (pt) | formulação lìquida de hormÈnio de crescimento, composição farmacêutica, forma de apresentação da formulação lìquida de hormÈnio de crescimento e uso da formulação lìquida de hormÈnio de crescimento | |
AR034226A2 (es) | Procedimiento perfeccionado para estabilizar proteinas. | |
MX2020009935A (es) | Formulaciones acuosas y estables de anticuerpos anti-tau. | |
AR070593A1 (es) | Composiciones efervescentes | |
ES2189458T3 (es) | Aditivo alimenticio quelado y metodo para su preparacion. | |
MY142020A (en) | Oral compositions for prevention and reduction of bacterial adhesion to oral surfaces | |
AR095971A1 (es) | Un método de curtido respetuoso del medio ambiente | |
MY150686A (en) | Oral composition containing morin | |
BR0313031A (pt) | Partìcula picante, produto alimentìcio, processo para a preparação de uma partìcula e uso de uma partìcula picante | |
TW200640369A (en) | Anti-bacterial composition and anti-bacterial material |